Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | GNG2 | P59768 | 2/20 | 0.50 |
| ▸ | GNB1 | P62873 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | GBA1 | P04062 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21816666 | 0.86 | PRKCI (0.51) | S1PR2PRKCIKMT2AMEN1GNG2 | |
| SCHEMBL12685297 | 0.84 | LMNA (0.56) | PRKCIKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL6502347 | 0.82 | PRKCI (0.53) | PRKCIKMT2AMEN1GNG2GNB1 | |
| SCHEMBL3556791 | 0.80 | CYP1A2 (0.43) | S1PR2PRKCIKMT2AMEN1RAB9A | |
| SCHEMBL13101029 | 0.79 | KMT2A (0.55) | PRKCIKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL23060364 | 0.77 | SMN1; SMN2 (0.51) | PRKCISMN1; SMN2CYP1A2TP53MAPT | |
| SCHEMBL23060363 | 0.77 | PRKCI (0.45) | PRKCIKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3554520 | 0.76 | PRKCI (0.41) | S1PR2PRKCIKMT2AMEN1RAB9A | |
| SCHEMBL26624138 | 0.76 | SORT1 (0.48) | PRKCISMN1; SMN2MAPTSORT1POLB | |
| SCHEMBL26624134 | 0.76 | PRKCI (0.44) | PRKCIKMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1554249-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005030209-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | S1PR2 851/4885PRKCI 3406/4885KMT2A 3265/4885 |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | S1PR2 1489/4885PRKCI 2812/4885KMT2A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.